Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

Oversea Chinese Banking Corp Ltd acquired a $30.17 million stake in Regeneron Pharmaceuticals during the first quarter, ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of ...

Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...

With the Trump administration poised to hike tariffs on Canadian goods to 35%, the equities market ended on a down note ...

This was the stock's fourth consecutive day of gains.

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...